This is a preview of subscription content, log in via an institution to check access.
References
Muss HB, Thor AD, Berry DA et al. C-erB-2 expression and response to adjuvant therapy in women with node positive breast cancer. New Engl J Med 1994; 330(18): 1260–66
Thor AD, Berry DA, Budman DR, et al. ERB-B2, p53 and efficacy of adjuvant therapy in lymph node positive breast cancer. J Nat Cancer Inst 1998; 18(90): 1346–60
Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node positive, hormone receptor negative breast cancer. J Nat Cancer Inst 1998; 18(90): 1361–70
Ravdin PM, Green S, Albain KS, et al. Initial report of SWOG biological correlative study of C-ERB-B2 expression as a predictor of outcome in a trial comparing adjuvant CAF-T with T (Tamoxifen) alone [abstract]. Proceedings of 34th Annual Meeting of the American Society of Clinical Oncology 1998; May 16–19; Los Angeles (CA); 17: 97a
Bianco AR, Laurentiis M De, Carlomagno C, et al. 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: evidence of interaction between C-ERB-B2 expression and tamoxifen efficacy [abstract]. Proceedings of 34th Annual Meeting of the American Society of Clinical Oncology 1998; May 16–19; Los Angeles (CA); 17: 97a
Yamauchi H, O’Neill A, Coelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/neu protein. J Clin Oncol 1997: 15(7): 2518–25
Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erb-B2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129–35
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ali, S.M. Trastuzumab. BioDrugs 12, 136–138 (1999). https://doi.org/10.2165/00063030-199912020-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199912020-00006